---
title: "KinLong released its first-quarter performance, with a net loss attributable to the parent company of 40.6143 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237826166.md"
description: "According to the Zhitong Finance APP, KinLong released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 1.206 billion yuan, a year-on-year decrease of 11.70%. The net loss attributable to shareholders of the listed company was 40.6143 million yuan. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 49.8735 million yuan"
datetime: "2025-04-28T11:01:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237826166.md)
  - [en](https://longbridge.com/en/news/237826166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237826166.md)
---

# KinLong released its first-quarter performance, with a net loss attributable to the parent company of 40.6143 million yuan

According to the Zhitong Finance APP, KinLong (002791.SZ) released its Q1 2025 report. In the first quarter, the company achieved operating revenue of 1.206 billion yuan, a year-on-year decrease of 11.70%. The net loss attributable to shareholders of the listed company was 40.6143 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 49.8735 million yuan

### Related Stocks

- [002791.CN](https://longbridge.com/en/quote/002791.CN.md)

## Related News & Research

- [ZAWYA: Al Habtoor Tower: Dubai's boldest residential project yet](https://longbridge.com/en/news/287051508.md)
- [31 SHIPS CROSSED THROUGH HORMUZ WITH IRGC'S HELP, REPORTS IRAN TV.](https://longbridge.com/en/news/287242948.md)
- [NEWLY FORMED MANHATTAN URANIUM RECEIVES APPROVAL TO DRILL AT NEVADA'S LARGEST PAST PRODUCING MINE](https://longbridge.com/en/news/287233635.md)
- [Al Jazeera: Iranian Official denies reports that Iran's Supreme Leader said that Uranium must stay in Iran.](https://longbridge.com/en/news/287236007.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)